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Abstract Extrusion of chemotherapeutics by ATP-binding
cassette (ABC) transporters like ABCB1 (P-glycoprotein) rep-
resents a crucial mechanism of multidrug resistance in cancer
therapy. We have previously shown that the 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor
simvastatin directly inhibits ABCB1, alters the glycosylation
of the transporter, and enhances the intracellular accumulation
of doxorubicin with subsequent anti-cancer action. Here, we
show that simvastatin reduces endogenous dolichol levels and
ABCB1 in human neuroblastoma SH-SY5Y cells.
Coapplication with dolichol prevents the downregulation of
the ABCB1 transporter. Importantly, dolichol also attenuated
simvastatin-induced apoptosis, unmasking involvement of un-
folded protein response. Direct monitoring of the fluorescent
fusion protein YFP-ABCB1 further confirms concentration-
dependent reduction of ABCB1 in HEK293 cells by simva-
statin. In simvastatin-treated murine xenografts, ABCB1 was
also reduced in the liver and rhabdomyosarcoma but did not
reach significance in neuroblastoma. Nevertheless, the in vivo
anti-cancer effects of simvastatin are corroborated by in-
creased apoptosis in tumor tissues. These findings provide
experimental evidence for usage of simvastatin in novel
chemotherapeutic regimens and link dolichol depletion to
simvastatin-induced anti-cancer activity.
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Introduction
The ATP-binding cassette (ABC) transporters are one of the
largest families of transmembrane proteins and dispose xenobi-
otics, lipids, and metabolic products across the plasma mem-
brane, mainly in an ATP-dependent manner (Dean and Annilo
2005; Fletcher et al. 2010). The overexpression of ABC trans-
porters is generally associated with resistance to chemotherapy,
which is prominently mediated by transporters like ABCB1 (P-
glycoprotein; MDR1), ABCC1, and ABCG2 (Gottesman et al.
2002; Cascorbi 2006; Robey et al. 2007; Fletcher et al. 2010).
ABCB1 is heavily glycosylated at asparagine residues 91, 94,
and 99, which are not affecting transport activity (Schinkel et al.
1993; Gribar et al. 2000; Kvackajova-Kisucka et al. 2001; Dean
andAnnilo 2005; Seres et al. 2011). Several studies have shown
that glycosylation is important for protein quality control in the
endoplasmic reticulum (ER) and trafficking to the plasmamem-
brane (Schinkel et al. 1993; Loo and Clarke 1998). Noteworthy,
inhibition of glycosylation of ABCB1 induced increased sensi-
tivity to different drugs (Hiss et al. 2007).
Three generations of ABCB1 inhibitors were developed to
counteract transporter-driven multidrug resistance in tumors
(Gottesman et al. 2002; Fletcher et al. 2010). At last, third-
generation compounds tariquidar, elacridar, and others are
specific and potent inhibitors of ABCB1, but due to severe
side effects and limited efficacy, clinical trials were declined
(Fox and Bates 2007; Abraham et al. 2009; Cripe et al. 2010).
Thus, it has been postulated that downregulation of ABCB1 or
inhibition of compensatory upregulation may represent a nov-
el pharmacological access to transporter-mediated multidrug
resistance (MDR) (Tamaki et al. 2011; Amiri-Kordestani et al.
2012).
Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase and thereby block the mevalonate
pathway, which results in reduced levels of cholesterol,
farnesyl pyrophosphate (FPP), and geranylgeranly pyrophos-
phate (GGPP) (Goldstein and Brown 1990). Based on this
mechanism of action, statins are widely used in the treatment
of cardiovascular diseases accompanied by hypercholesterol-
emia (Demierre et al. 2005; Gazzerro et al. 2012; Taylor et al.
2013). Beside this cholesterol-lowering effects, so-called
pleiotropic effects have emerged, which are in part explained
by reduction of intermediates of the mevalonate pathway
(Goldstein and Brown 1990; Takemoto and Liao 2001;
Gazzerro et al. 2012). The isoprenoids FPP and GGPP are
involved in the posttranslational modifications of several pro-
teins, such as small G proteins, which play a critical role in
maintenance of cell shape, motility, differentiation, and prolif-
eration (Demierre et al. 2005; Gazzerro et al. 2012).
Moreover, dolichol, a side product of the mevalonate pathway,
is an important lipid carrier for the glycan precursor in N-
linked glycosylation of proteins in the ER (Behrens and
Leloir 1970; Cantagrel and Lefeber 2011).
Statins’ anti-tumor effects have been investigated in many
cellular systems (Farmer 2000; Werner et al. 2004; Demierre
et al. 2005; Minichsdorfer and Hohenegger 2009;
Sieczkowski et al. 2010; Gazzerro et al. 2012; Chang et al.
2013). Previous studies indicate that human melanoma, neu-
roblastoma, and rhabdomyosarcoma cells are susceptible to
statin-induced apoptosis via the mitochondrial pathway
(Werner et al. 2004, 2013; Minichsdorfer and Hohenegger
2009; Sieczkowski et al. 2010). Indeed, statins also directly
inhibit ABCB1 in many cellular systems, e.g., with an IC50 of
9 μM for simvastatin or 26 μM for lovastatin (Wang et al.
2001; Goard et al. 2010; Martirosyan et al. 2010; Sieczkowski
et al. 2010; Werner et al. 2013). The coapplication of simva-
statin or lovastatin with doxorubicin, a well-known ABCB1
substrate, increased the accumulation of the anthracycline in
many cellular systems and resulted in enhanced nuclear accu-
mulation, potentiated DNA damage, and apoptosis (Goard
et al. 2010; Martirosyan et al. 2010; Sieczkowski et al. 2010;
Werner et al. 2013). Beside this immediate blockade of
ABCB1, we also observed reduced levels of ABCB1 in mem-
branes from simvastatin-treated rhabdomyosarcoma and neu-
roblastoma cells (Sieczkowski et al. 2010;Werner et al. 2013).
The downregulation of ABCB1 affected mainly the fully gly-
cosylated 170-kDa band compared to the core-glycosylated
140-kDa band. This is a clear indication for an involvement
of statins in the glycosylation of the ABCB1 transporter
(Sieczkowski et al. 2010). Finally, downregulation of
ABCB1 by a preincubation with simvastatin was sufficient
to result in reduced calcein efflux rates in rhabdomyosarcoma
(RD) cells (Werner et al. 2013).
Hence, the aim of this study was to show whether statin
exposure to human neuroblastoma cells has an impact on en-
dogenous dolichol levels and whether coadministration of
dolichol could prevent ABCB1 downregulation and apoptosis.
Moreover, induction of apoptosis and reduction of ABCB1 by
simvastatin was evaluated in vivo by murine xenograft models
with rhabdomyosarcoma and neuroblastoma cells.
Materials and methods
Chemicals and reagents
Simvastatin was purchased from Merck (Darmstadt,
Germany), and all other reagents and chemicals from Sigma-
Aldrich (St. Louis, MO, USA) or Carl Roth (Karlsruhe,
Germany), if not otherwise stated.
Cell culture
Experiments were performed with human neuroblastoma
(SH-SY5Y), rhabdomyosarcoma (RD), and human embryon-
ic kidney (HEK)-293 cells (ATCC–LGC Standards, Wesel,
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Germany). SH-SY5Y cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM)/Ham’s F12 medium,
HEK-293, and RD cells in DMEM high glucose medium,
all supplemented with 10 % fetal bovine serum and 1 %
penicillin/streptomycin and kept in humidified atmosphere
of 5 % CO2 at 37 °C.
Lipid extraction and chromatography
SH-SY5Y cells (1×107) were treated according to the figure
legend and lysed in methanol plus 3 % acetic acid (v/v), sup-
plemented with the same volume of hexane and vortexed vig-
orously. Lipid extraction into the upper phase was repeated
and collected, and the organic solvent evaporated. The collect-
ed lipids were dissolved in CHCl3 and separated by thin-layer
chromatography (TLC) using TLC Silica gel 60 plates
(Merck; Darmstadt, Germany) and hexane including 20 %
ethyl acetate as mobile phase. The separated lipids were visu-
alized by CuSO4 and heating of the plate. C80-105 dolichol,
isolated from bovine heart, and C55 dolichol were used as
standards. Samples corresponding to the relative motility of
the dolichol standards were scratched and transferred to a
glass column retaining thematrix of the TLC. Dolichol elution
from the silica gel was accomplished by 500 μl CHCl3 and
repeated four times. The eluate was collected, evaporated,
dissolved in 20 μl 2-propanol/methanol/n-hexane
(45:45:10), and applied to high-performance liquid chroma-
tography (HPLC). Dolichol fractions were separated with the
running buffer (propanol/methanol/n-hexane, 45:45:10) at
1.7 ml/min (Hitachi pump L-2130 and UV detector L-2400;
Tokyo, Japan) using C55 dolichol or cholesterol as an internal
standard. Peaks were analyzed with Elite LaChrom software
(Hitachi; Tokyo, Japan).
Cell lysis and membrane extraction
Untreated and simvastatin-exposed SH-SY5Y cells were
washed with phosphate-buffered saline (PBS), shock-
frozen with liquid nitrogen, and lysed in RIPA buffer
(50 mM Tris-HCl, pH 8.0; 150 mM NaCl; 10 mM glyc-
erophosphate; 0.1 % SDS; 1 % NP-40) containing pro-
tease inhibi tors aprot inin (2 μg/ml), leupept in
(10 μg/ml), and pefablock (1 mM). Phosphatase inhibi-
tors NaF (1 mM) and Na3VO4 (1 mM) were supple-
mented to detect phosphorylated protein species. After
10 min on ice, cells were again shock-frozen in liquid
nitrogen and centrifuged with 30000×g for 30 min at
4 °C. The supernatant fractions were used for Western
blots. Protein concentrations were determined with
Bradford protein assay using bovine serum albumin as
a protein standard (Bradford 1976).
Caspase 3 activity
The fluorescence-based caspase 3 assay was carried out as
previously described (Sacher et al. 2005; Werner et al. 2013).
PCR
Following drug treatment, total RNA from SH-SY5Y
cells was isolated using RNeasy Mini Kit (Qiagen,
Hilden, Germany). After reverse transcription (RevertAid
First Strand cDNA Synthesis Kit; Thermo Scientific;
Waltham, MA, USA), the cDNA was used for quantitative
(real-time) PCR using SensiMix SYBR and Fluorescein
(GenXpress, Vienna, Austria) and the specific primers
given in Table 1. Quantitative PCR was initiated by a step
of denaturation at 94 °C for 3 min, followed by 40 cycles
of denaturation at 94 °C for 1 min, annealing at 50 °C for
30 s, and DNA synthesis at 72 °C for 30 s. The final
melting step included denaturation at 95 °C for 15 s,
60 °C for 15 s, a linear temperature gradient to 95 °C in
20 min, and 95 °C for 15 s. CT values were normalized to
the four control genes (B2M, RPLP0, RPS14, and
GAPDH), and quantification was performed using the
comparative CT method. The PCR for ER stress markers
(BiP and CHOP) was run under identical conditions ex-
cept for 30 cycles, an annealing temperature of 58 °C, and
normalization to GAPDH.
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FACS analysis
SH-SY5Y cells (5×105) were treated with simvastatin as in-
dicated in figures, and surface ABCB1 transporter was
mapped with MRK16 antibody (1:100 dilution in PBS,
30 min at room temperature; Kamiya Biomedical Company,
Seattle, WA, USA) and visualized with the corresponding
Alexa Fluor®488-conjugated goat anti-mouse antibody
(1:100 in PBS, 30 min at 4 °C; Invitrogen, CA, USA).
Alternatively, C219 (Abcam, Cambridge, UK) or p170
(Neomarkers, Fremont, CA, USA) antibodies (1:50 in 10 %
FCS with 1 % NaN3 in PBS, 2 h at room temperature) were
used for ABCB1 staining in fixed cells and gave similar re-
sults. In all FACS experiments, unstained cells and/or cells
mapped with mouse IgG2a (Becton Dickinson, Heidelberg,
Germany) were used as negative controls to correct for back-
ground. The data were processed off-line with Flowing soft-
ware (www.flowingsoftware.com).
Apoptosis was determined with biparametric FACS analy-
sis using FITC-conjugated annexin V (Ebioscience, San
Diego, CA, USA) and propidium iodide (PI) as previously
described (Minichsdorfer and Hohenegger 2009).
Rhodamine 123 efflux
Rhodamine 123 efflux was performed as previously described
by Donmez Cakil et al. (Donmez Cakil et al. 2014). Briefly,
SH-SY5Y cells (1×106) were exposed to increasing concen-
trations of simvastatin for 48 h, washed, and incubated with
0.53 μM rhodamine123 for 30 min at 37 °C. Fluorescence
(excitation at 488 nm and emission wavelength at 534 nm)
was continuously monitored (5 min) with a FACSCalibur.
Surface expression of ABCB1 was controlled by FACS with
MRK16 staining, and off-line analyses were done with
CellQuest software (Becton Dickinson, Heidelberg,
Germany), as previously described (Chiba et al. 1996;
Donmez Cakil et al. 2014).
Protein turnover of YFP-ABCB1 fusion protein
HEK-293 cells (5×106) were transfected with 0.4 μg YFP-
ABCB1-pcDNA3 plasmid using TurboFect following the
manufacturer’s protocol (Thermo Scientific; Waltham, MA,
USA). The NH2-terminal-tagged YFP-ABCB1 construct
was kindly provided by Prof. Peter Chiba (Institute of
Medical Chemistry) and Dr. Oliver Kudlacek (Institute of
Pharmacology, Medical University of Vienna). After 48 h of
recovery, cells were treated for another 48 h in the absence or
presence of cycloheximide (10 μg/ml), doxorubicin (0.1 μM),
simvastatin (1 or 3 μM), or vehicle (empty pcDNA3 plasmid).
Thereafter, cells were shock-frozen and resuspended in PBS,
and the YFP fluorescence (exCitation 515 nm, emission
530 nm) was measured with a fluorescence spectrophotometer
(FL-4500 Hitachi; Tokyo, Japan). Signals were corrected for
protein concentration and background signal of the vehicle
(FL-Solutions 2.0 software; Hitachi; Tokyo, Japan).
Murine xenograft experiments
Two xenograft experiments were performed and approved by
the Animal Welfare Committee of the Medical University of
Vienna and the Austrian Science Ministry (GZ66.009/0271-
BrGT/2005 and GZ66.009/0274-II/3b/2010). Female CD-1
Nu/Nu mice (6 weeks old; Charles River; Sulzfeld,
Germany) were subcutaneously inoculated with SH-SY5Y
neuroblastoma cells (1×107 in PBS) into the left and right
flank. Twelve days after inoculation, groups of four mice were
assigned to control group or simvastatin (4.25 mg/kg/day;
oral) group. In both groups, one inoculum did not turn into a
tumor. A day–night rhythm was emulated by light every 12 h,
and the welfare of the animals was checked every day. The
animals were killed by neck dislocation after 2 months or
earlier due to critical tumor size. Organs and tumors were
excised and weighted, and aliquots were rapidly frozen in
liquid nitrogen and stored at −80 °C for further analyses.
Under similar conditions, female CD-1 Nu/Nu mice were
inoculated with rhabdomyosarcoma (RD) cells (1.5×106 cells
in PBS) into the right flank. One week after inoculation, ani-
mals received water (control; n=10), simvastatin (1.15 mg/kg/
day; n=6), cyclophosphamide (2 mg/kg/day; n=6), or a com-
bination of simvastatin and cyclophosphamide (n=6). The
animals were killed after 54 days or earlier due to critical
tumor size. Tumors and livers were excised, weighted, and
fixed in 4 % paraformaldehyde for staining and immunohis-
tochemistry. Small aliquots of organs and tumors were also
rapidly frozen in liquid nitrogen and stored at −80 °C for
further analyses.
For tissue analysis, liver and tumor samples (25–50 mg)
were homogenized in solution A (10 mM HEPES, pH 7.5;
10 % sucrose; 5 mM EDTA; 1 mM DTT; 1 mM pefablock;
100 μM aprotinin; 100 μM leupeptin; 10 μM calpain inhibi-
tors I and II). Lysates were centrifuged at 100×g for 5 min, and
the supernatant was centrifuged again with 600×g for 10 min.
The supernatant was again centrifuged at 11,600×g for
20 min. At last, the supernatant was centrifuged again at
100,000×g for 45 min. Pellet corresponding to the membrane
fraction was resuspended in 100–200 μl solution B (10 mM
HEPES, pH 7.5; 10 % sucrose; 2 mM EDTA; 1 mM DTT)
supplemented with the above protease inhibitors and stored at
−80 °C. All steps were carried out at 4 °C.
Immunohistochemical analysis of tumors
Tumors were embedded in optimal cutting temperature com-
pound (OCT Tissue-Tek, Sanova, Vienna, Austria) prior to
frozen sectioning on a microtome cryostat (Microm HM-
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500-OM, Walldorf, Germany). Alternatively, samples were
fixed with 5 % formalin buffered in PBS. Sections were cut
(3–5 μm) and formalin was removed by increasing concentra-
tions of ethanol. If necessary, sections were dehydrated by
methanol and again hydrated in water. Fixed slices were incu-
bated with 4 % paraformaldehyde and then blocked with 4 %
bovine serum albumin in PBS. Nuclei were stained with
Hoechst 33258 (15 min) and activated caspase 3 with an an-
tibody selective for cleaved caspase 3 (1:200, overnight; Cell
Signaling, Millipore, Vienna, Austria). Immunoreactive spe-
cies were detected with a corresponding Cy3-conjugated an-
tibody (1:200; excitation 543 nm, emission 570 nm; PA43004,
GE Healthcare, Vienna, Austria), and images were taken with
a Zeiss fluorescence microscope (Axioimager Z1, Jena,
Germany).
Western blot analysis
Proteins (15–30 μg) were separated on a 7 or 10 % SDS-
PAGE, transferred to nitrocellulose membranes, blocked with
5 % bovine serum albumin, and incubated overnight at 4 °C
with the following primary antibodies: ABCB1 (C219, 1:300;
Merck; Darmstadt, Germany), cleaved poly-ADP ribose po-
lymerase (cleaved PARP, 1:1000; Cell Signaling Millipore,
Vienna, Austria), extracellular-signal-regulated protein ki-
nases 1 and 2 (ERK1/2) and phospho-ERK1/2 (1:2000; Cell
Signaling Millipore, Vienna, Austria), actin (AC-40, 1:20,
000), or α-tubulin (anti-α tubulin, 1:40,000). Proteins of in-
terest were visualized by enhanced chemiluminescence (ECL)
system (ECL Plus, GE Healthcare, Vienna, Austria) using a
species-corresponding horseradish peroxidase (HRP)-conju-
gated secondary antibody (1:10,000 in 2 % BSA; Cell
Signaling Cell Signaling Millipore, Vienna, Austria) for 1 h
at room temperature. Actin and α-tubulin were alternatively
used as loading controls depending on compatibility with spe-
cies of the antibody andmolecular mass range of the protein of
interest. Three independent experiments were carried out for
Western blots, and samples were used up to three times to
repeat and optimize X-ray exposure times for ECL detection.
Bands of interest were quantified and analyzed using ImageJ
software (http://rsbweb.nig.gov/ij/).
Statistical analysis
Typically, three independent experiments were carried out in
duplicates (n=3) and the data are presented as mean±standard
deviation (SD) if not otherwise stated. Statistical analyses
were performed using SigmaPlot software (Jandl, Erkrath,
Germany) with either unpaired Student’s t test or for multiple
comparisons ANOVA and Holm–Sidak test or post hoc Tukey
test. A p value <0.05 is considered statistically significant.
Results
ABCB1 downregulation in simvastatin-treated SH-SY5Y
cells
Simvastatin reduces the fully glycosylated form of the
ABCB1 transporter in rhabdomyosarcoma (RD) and SH-
SY5Y neuroblastoma cells shown by Western blots
(Sieczkowski et al. 2010; Werner et al. 2013). In order to
quantify this effect, we here confirm significant reduction of
cell surface ABCB1 protein expression in simvastatin-treated
SH-SY5Y neuroblastoma cells by FACS analysis (Fig. 1a–c).
The kinetics of cell surface reduction of ABCB1 is detected
with MRK16 antibody in non-permeabilized SH-SY5Y neu-
roblastoma cells. ABCB1 reduction is hardly observed after
24-h simvastatin exposure (Fig. 1b), indicating an early com-
pensatory mechanism. However, a significant reduction of
ABCB1 surface expression is observed after 48 h with already
1 μM simvastatin (Fig. 1c).
In order to further confirm ABCB1 downregulation by
simvastatin in another experimental setting including also in-
tracellular ABCB1, the fluorescent fusion protein YFP-
ABCB1 was heterologously expressed in HEK-293 cells
(Fig. 1d). This experimental setup was validated by doxoru-
bicin as a positive control for upregulation of the ABC trans-
porter and cycloheximide as a negative control mirroring tran-
scriptional inhibition. A concentration of 3 μM simvastatin
was sufficient to reduce the transporter within 48 h significant-
ly. Simvastatin had no effect on the fluorescence signal of
YFP-ABCB1 in the presence of cycloheximide, a blocker of
translational elongation. Accordingly, inhibition of transcrip-
tion is considered to be responsible for the simvastatin-
dependent reduction of ABCB1 protein. These findings to-
gether with previous reports confirm that simvastatin in the
low micromolar concentration range downregulates ABCB1
on protein level, which accounts for a 20–40 % reduction,
depending on the experimental conditions (Fig. 1)
(Sieczkowski et al. 2010; Werner et al. 2013).
Accordingly, one would expect a decrease of ABCB1
messenger RNA (mRNA) levels in the presence of sim-
vastatin. The tissue distribution, spectrum of substrates
and regulators, and the role in multidrug resistance are
overlapping for ABCC1 and ABCG2 with ABCB1
(Sharom 2008). In contrast, little is known about
ABCC6 in regard to multidrug resistance and compensa-
tion of ABCB1 downregulation (Vanakker et al. 2013). A
significant reduction of ABCB1, ABCC1, and ABCG2
mRNA is already seen after 6 h of simvastatin exposure,
which is further enhanced upon longer incubation times
(Fig. 1e, f). The amount of ABCC6 mRNA is not affected
and documents specificity of the simvastatin effect. Most
prominently, mRNA of ABCB1 and ABCC1 is already
downregulated by 1 μM simvastatin. Noteworthy, these
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findings are not indicative for a compensatory upregula-
tion of alternative transporters like ABCC1 and ABCG2.
Transporter activity of ABCB1 is affected by simvastatin
Functionally, statins directly inhibit ABCB1 (Bogman et al.
2001; Wang et al. 2001; Goard et al. 2010; Martirosyan et al.
2010; Sieczkowski et al. 2010; Werner et al. 2013). In order to
confirm previous findings using calcein-AM, we here
determined first-order rate constants of rhodamine 123 efflux
which were plotted against the corresponding expression of
ABCB1. This approach allowed correcting for different ex-
pression levels of the transporter, which was reduced in the
presence of simvastatin (Fig. 2a). The slopes of such linear
regressions yield rhodamine 123 transportation rates (Fig. 2b),
which were significantly reduced by simvastatin in a
concentration-dependent manner. However, a significant dif-
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Fig. 1 Downregulation of
ABCB1 by simvastatin. SH-
SY5Y cells were exposed to the
indicated simvastatin (Sim)
concentrations and compared to
controls (CTL). Cell surface
expression of ABCB1 was
monitored by FACS analysis with
the MRK16 antibody (a–c). A
histogram is depicted in panel (a),
the kinetics are given in panel (b)
(n=3) and concentration
dependency in panel (c) (n=3).
HEK-293 cells were transfected
with YFP-ABCB1-pcDNA3, and
after 48 h, the cells were exposed
to doxorubicin (Dox; 0.1 μM),
cycloheximide (CHX; 10 μg/ml),
and various concentrations of
simvastatin for additional 2 days
(d) (n=3). Quantitative PCR of
various ABC transporters is
depicted from simvastatin-treated
SH-SY5Y cells for 6 h (e) or 72 h
(f) (n=6–12). All values were
presented as mean±SD and
corrected for background
fluorescence. Significance was
tested with one-way ANOVA
(Holm–Sidak method). Asterisks
denote significance versus control
(*p<0.05; **p<0.005;
***p<0.0005)
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Simvastatin depletes cells from endogenous dolichol
In support to our conjecture, that glycosylation of proteins is
impaired by simvastatin exposure, we have determined en-
dogenous dolichol levels in SH-SY5Y cells (Fig. 3)
(Sieczkowski et al. 2010). Expectedly, simvastatin exposure
reduced endogenous dolichol levels in a concentration-
dependent manner (Fig. 3b). Noteworthy, a significant reduc-
tion of dolichol was observed already at 0.1 μM simvastatin
compared to untreated cells (Fig. 3c, d).
Dolichol phosphate is a downstream product of the
HMG-CoA reductase and critically required for glycopro-
tein biosynthesis (Behrens and Leloir 1970; Goldstein and
Brown 1990). One would now postulate that dolichol C80-
105 coapplication prevents downregulation of ABCB1 by
simvastatin (Fig. 4a–d). Interestingly, the addition of
dolichol alone, but also in the presence of simvastatin,
strongly intensified the ABCB1 bands, indicating full sat-
uration of the glycosylation machinery. Conversely, with
simvastatin alone, a significant downregulation of
ABCB1 is detectable at 24 h and longer incubation times
(120 h, Fig. 4c, d). Importantly, the addition of dolichol
significantly protected from simvastatin-induced down-
regulation of ABCB1 (Fig. 4c, d). The protein bands for
ABCB1 are fuzzy and broad, as this is assumed to be due
to different levels of glycosylation, in particular in the
presence of exogenous dolichol. Similar findings have
been described by others previously (Loo and Clarke
1999; Gribar et al. 2000; Zhang et al. 2004; Seres et al.
2011). However, the reduction of ABCB1 is specific since
protein levels of α-tubulin and ERK1/2 were not affected
by simvastatin or dolichol (Fig. 4f). Moreover, the well-
described inhibitory effect of statins on ERK1/2 phos-
phorylation is seen in simvastatin-exposed probes and sig-
nificantly reversed by coadministration with dolichol
(Fig. 4g) (Campbell et al. 2006). Noteworthy, dolichol
per se significantly reduced ERK1/2 phosphorylation,
which is currently not understood.
The dolichol dependency of simvastatin effects was also
observed on the level of apoptosis. The cleaved PARP frag-
ment significantly accumulates in simvastatin exposed cell
extracts and is reduced by coadministration of dolichol
(Fig. 4b, e). This observation is supported by simvastatin-
dependent activation of caspase 3 and positivity for annexin
V/PI staining, which were again significantly reduced by
coadministration with dolichol (Fig. 5). Thus, impairment
of glycosylation in the endoplasmic reticulum (ER) leads
to reduction of heavily glycosylated proteins but also to
cellular stress resulting in apoptosis. Mechanistically, this
can be explained by simvastatin-induced ER stress, which
is detected by the upregulation of the specific genes like
BiP/GRP78 and the transcription factor CCAAT/enhancer-
binding protein (C/EBP)-homologous protein (CHOP)
(Table 2) (Haataja et al. 2008; van Schadewijk et al.
2012). Already at 0.1 μM simvastatin, BiP and CHOP were
significantly induced, while at 10 μM simvastatin, no induc-
tion of the ER chaperone BiP was observable. An explana-
tion for this latter observation is currently not available.
Alexa Fluo488 fluorescence (MFU)
































































Fig. 2 Simvastatin reduces rhodamine 123 transport rates in SH-SY5Y
cells. SH-SY5Y cells were treated with the indicated simvastatin (Sim)
concentrations for 48 h and loaded with rhodamine 123. The rhodamine
123 efflux was monitored by FACS analysis and fitted to a mono-
exponential decay, and the corresponding first-order rate constants were
plotted against the fluorescence of the MRK16/Alexa Fluo488
fluorescence, which was used as a measure for ABCB1 surface
expression of the corresponding measurement (mean fluorescence units,
MFU). The data points represent nine individual measurements of four
control experiments (CTL) and seven individual measurments of three
experiments in the presence of 0.1 μM simvastatin (Sim) (a). The
transportation rates in the absence (CTL) and presence of simvastatin
(Sim) (b). Data represent mean±SD (n=4; 0.1 μM Sim, n=3; *p<0.05)
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In vivo effects of simvastatin on tumor growth
and ABCB1 expression
In order to confirm in vivo relevance of our findings, CD-1
Nu/Numice were inoculated with either SH-SY5Y neuroblas-
toma cells or RD rhabdomyosarcoma cells, and simvastatin
was applied orally, 4.25 or 1.15 mg/kg/day, respectively.
These doses of simvastatin translate into a human equivalent
dose of 7 and 20 mg, which is a typical starting dose for
simvastatin (Reagan-Shaw et al. 2008; Gazzerro et al. 2012).
There was no significant difference between the body
mass of control and simvastatin-treated mice in both
models (Table 3 and Fig. 6a). In the neuroblastoma xeno-
graft model, there was also no significant difference in
organ weights (Table 3), indicating no gross metastatic
activity. Conversely, tumor weight in simvastatin-treated
mice was diminished in comparison to control animals;
however, this decrease was only significant in the RD
xenograft model (Table 3 and Fig. 6b).
Following oral administration, simvastatin reaches the
highest concentrations in the liver (Gazzerro et al. 2012).
Accordingly, ABCB1 was significantly reduced in tissue
homogenates from liver of simvastatin-treated animals
(Figs. 6 and 7). Moreover, a similar trend was observed
in rhabdomyosarcoma and neuroblastoma, which was
Fig. 4 Dolichol restores simvastatin-induced ABCB1 downregulation
and prevents apoptosis. SH-SY5Y cells were treated with simvastatin
(Sim) in the absence and presence of dolichol C80-105 (Dol) for 24 (a, c)
or 120 h (b, d–g) and probed for ABCB1, cleaved PARP, ERK1/2, and
phosphorylated ERK1/2.α-Tubulin was used as a loading control and the
molecular mass of the protein standards or proteins of interest are
indicated (kDa). Western blots show a representative experiment, which
was repeated two times. Panels (c)–(g) depict the densitometric analyses
of the proteins of interest as shown in a representative experiment in
panels (a) and (b) (n=3). Intensities were normalized to the loading
controls and given as percent of control. Asterisks denote significance
versus control in the absence of the simvastatin (*p<0.05; **p<0.005;
n.s. denotes not significant). Hatches denote significance versus the
























Fig. 3 Simvastatin depletes SH-
SY5Y cells from endogenous
dolichol. HPLC analysis of
dolichol C80-105 standard (a) was
compared with endogenous
dolichol levels in SH-SY5Y cells
of controls (CTL) (c) and
simvastatin-treated cells (48 h)
(d). Absorption units denote AU
and mAU. The areas under the
curve of the dolichol C80-105
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only significant in rhabdomyosarcoma (cf., Figs. 6 and 7).
Taken together, these in vitro findings confirm that sim-
vastatin is able to downregulate ABCB1 also in vivo at
pharmacological relevant dosages.
In vivo detection of simvastatin-induced apoptosis
in tumors
Besides the downregulation of ABCB1 and a direct inhibition
of the transporter, simvastatin triggers also apoptosis in rhab-
domyosarcoma and neuroblastoma cells (Werner et al. 2004,
2013; Sieczkowski et al. 2010). This pro-apoptotic effect of
simvastatin is now also confirmed in vivo. Simvastatin in-
duced significant PARP cleavage in neuroblastoma (Fig. 7e,
f) and cleavage of caspase 3 in rhabdomyosarcoma (Fig. 8). In
the latter xenograft model, cyclophosphamide was applied as
positive control for anti-tumor activity, without being a sub-
strate for ABCB1. Importantly, reduction in tumor mass
(Fig. 6b) and the activation of caspase 3 (Fig. 8) were triggered
by cyclophosphamide to the same extent compared to simva-
statin or even further enhanced by coapplication. Thus, statins
like simvastatin might serve as a partner in novel chemother-
apeutic combinations even independent of ABCB1 substrates
as this has been postulated previously (Demierre et al. 2005;
Gazzerro et al. 2012).
Discussion
Statin treatment alters the glycosylation pattern of ABCB1 in
neuroblastoma and rhabdomyosarcoma cells, similar to
tunicamycin or PNGase F treatment (Sieczkowski et al.
2010; Werner et al. 2013). The ABCB1 transporter exists in
a full glycosylated 170-kDa formwhich upon deglycosylation
shifts to the core glycosylated 140-kDa species (Loo and
Clarke 1999). Although impaired glycosylation leads to a re-
duction in cell surface expression, the protein is still functional
as this has been shown in various cellular systems (Germann
et al. 1990; Kuchler and Thorner 1992; Loo and Clarke 1999).
The detection of ABCB1 by Western blot results in diffuse
and fuzzy bands surrounding the 170- and 140-kDa region,
due to the different levels of glycosylation (Loo and Clarke
1999; Greer and Ivey 2007; Seres et al. 2011). We also ob-
served diffuse bands in particular in the presence of dolichol,
which supports the conjecture that the level of glycosylation
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Fig. 5 Dolichol restores simvastatin-induced apoptosis. Caspase 3
activation is monitored in lysates from SH-SY5Y cells treated with
simvastatin (Sim) in the absence (CTL) and presence of dolichol C80-
105 for 48 h (a). Similar treated cells were analyzed for apoptosis by
FACS analysis of annexin V/PI-positive cells (b). The symbols
represent mean±SD (n=3). Asterisks denote significance versus control
(*p<0.05; **p<0.01; ***p<0.005)
Table 2 Simvastatin-induced unfolded protein response
Simvastatin (μM) BiP (a.u.) CHOP (a.u.)
0 1 1
0.1 1.37±0.10 (**) 1.64±0.12 (**)
1 1.28±0.04 (**) 1.39±0.13 (*)
10 1.06±0.05 (n.s.) 2.35±0.27 (***)
Markers for ER stress, BiP and CHOP, were detected on mRNA level by
PCR and normalized to GAPDH values from probes treated with increas-
ing simvastatin concentrations for 48 h (mean±SD, n=3)
(*p<0.02; **p<0.005; ***p<0.001; n.s. denotes not significant; statisti-
cal significance is calculated with one-way ANOVA and Holm–Sidak
method
Table 3 Analysis of the neuroblastoma xenograft experiment
Control Simvastatin
Liver (n=4) 1.49±0.14 1.59±0.24 (n.s.)
Heart (n=4) 0.14±0.02 0.13±0.01 (n.s.)
Spleen (n=4) 0.19±0.06 0.18±0.05 (n.s.)
Kidney (n=8) 0.53±0.20 0.52±0.10 (n.s.)
Lung (n=4) 0.21±0.05 0.20±0.02 (n.s.)
Tumor (SH-SY5Y cells; n=7) 2.77±1.87 2.25±1.61 (n.s.)
Body weight (n=4) 34.48±4.54 36.06±5.51 (n.s.)
Postmortem, the organs of four mice in each group were weighted (g) and
presented as mean±SD. In both groups, one tumor was not detectable.
Comparison of the two groups with Student’s t test revealed no statistical
significance (n.s.)
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core glycosylated species (Fig. 4). In the presence of simva-
statin, the overall amount of ABCB1 is reduced and thereby
also the intensities of the 140-kDa core glycosylated band,
which may explain that, in some cases, the shift from the
170 to the 140-kDa form is hardly pronounced. Another ex-
planation for the heterogeneity of ABCB1 glycosylation is
depending on cellular systems, in particular transformed ver-
sus untransformed cells (Ichikawa et al. 1991; Fakla et al.
1998). For example, the different glycosylation branches have
been found to be alternatively bisected at ß(1-4)-N-acetyl-D-
glucosamine residues (GlcNAc) in transformed cells.
Nevertheless, we can exclude a methodical issue since other
proteins are readily detected in these samples, like ERK1/2,
cleaved PARP, or α-tubulin (Fig. 4).
The cell surface expression of ABCB1 in SH-SY5Y neu-
roblastoma cells is significantly reduced for longer incubation
times in the presence of simvastatin (Fig. 1). This decline in
ABCB1 expression is supported by Western blots of whole
cell lysates probed for total ABCB1, which showed only a
slight reduction after 24-h simvastatin exposure compared to
120-h incubations (Fig. 4a–d). This reduction of ABCB1 is
considered to be not due to enhanced protein degradation,
since the expression of the fusion protein YFP-ABCB1 is
not further reduced in the presence of cycloheximide plus
simvastatin compared to cycloheximide alone. Conversely,
in the absence of transcriptional inhibition, simvastatin re-
duced YFP-ABCB1 within 48 h to the level obtained with





































































































xenograft model. Female CD-1
Nu/Nu mice were inoculated with
human RD rhabdomyosarcoma
cells and then assigned to the
following groups: control (CTL;
n=10), 1.15 mg/kg/day
simvastatin (Sim; n=6), 2 mg/kg/
day cyclophosphamide (Cyc; n=
6), and a combination therapy
(Cyc+Sim; n=6). The
postmortem body mass (a) and
tumor weight is given as mean±
SD (b). Representative Western
blot analyses of individual
samples of different livers and
rhabdomyosarcoma tissues were
probed for ABCB1 and α-tubulin
as a loading control (c). Intensities
of protein bands of interest were
normalized to the loading control
(d, e). Significance was calculated
versus control with one-way
ANOVA (Holm–Sidak method)
or Student’s t test (n.s. denotes not
significant; *p<0.05;
***p<0005)
Naunyn-Schmiedeberg's Arch Pharmacol (2016) 389:17–32 27
corroborated by qPCR and a significant downregulation of
mRNA for ABCB1, ABCC1, and ABCG2 over time
(Fig. 1e, f). A compensatory upregulation of ABCC1 or
ABCG2 is not observed, although these transporters share
overlapping drug specificity and importance in multidrug re-
sistance (Sharom 2008). In contrast, the mRNA for ABCC6 is
hardly affected by simvastatin, indicating the specificity of the
drug effect. A significant reduction of mRNA and functional
activity for ABCB1 has been previously described in human
hepatoma and blood cells (Rodrigues et al. 2006).
Interestingly, in these cellular systems, 10 to 20 μM of ator-
vastatin caused an increase of ABCB1 on protein level.
Importantly, our findings have been verified by various
methods (heterologous expression of YFP-ABCB1, FACS,
and Western blots) and different antibodies against ABCB1
(C219, MRK16) in order to control for unspecific reactivity.
In particular, heterologous expression of YFP-ABCB1 enabled
direct monitoring in simvastatin-treated HEK-293 cells and cor-
roborated downregulation in a concentration-dependentmanner
(Fig. 1d), while the anthracycline doxorubicin, a known induc-
tor of ABCB1, significantly augmented YFP-ABCB1.
Besides plasmamembrane, ABCB1 has been allocated to the
endoplasmic reticulum, various endosomes, Golgi, and lyso-
somes, but not mitochondria (for review see (Fu and Arias
2012)). This intracellular organelle pattern reflects the protein
synthesis, maturation and posttranslational modification, the
translocation to the target membrane, and the degradation, re-
spectively. Posttranslational modification of ABC transporters
by N-glycosylation has been investigated intensively and plays
a critical role in protein folding, protein export, and maintenance
of protein stability (Richert et al. 1988; Asano et al. 1993;
Schinkel et al. 1993; Lee et al. 2003; Zhang et al. 2004;
Urquhart et al. 2005). Indeed, simvastatin reduced endogenous


































































































Fig. 7 Neuroblastoma xenograft
model. Female CD-1 Nu/Numice
were inoculated with human SH-
SY5Y cells and assigned to
control (CTL), or 4.25 mg/kg/day
simvastatin (Sim) groups of four
animals. Postmortem, tissues
from liver (a, b) and
neuroblastoma (c–f) were probed
for ABCB1 and PARP, with actin
and α-tubulin as a loading
control. Representative Western
blots are depicted (a, c, e), and the
intensities of the proteins of
interest were normalized to the
loading control of all experiments
(n=3–5) (b, d, f). Statistical
significance was calculated with
Student’s t test (n.s. denotes not
significant; **p<0.005)
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protein glycosylation in the ER (Behrens and Leloir 1970).
Others have shown that inhibition of glycosylation augments
ubiquitination and degradation of ABCB1 (Kramer et al.
1993; Seres et al. 2011). Importantly, altered glycosylation does
not affect the transport activity of ABCB1 (Germann et al. 1990;
Kuchler and Thorner 1992; Schinkel et al. 1993; Loo andClarke
1999; Seres et al. 2011), whereas ER trafficking is impaired
(Loo and Clarke 1998). In non-polarized cells, approximately
30 % of the ABCB1 is found in EAA1- and Rab5-positive
endosomes which shuttle between the plasma membrane and
thereby control the cell surface expression of ABCB1 (Kim
et al. 1997). It is known that Rab proteins control vesicle trans-
port by interaction with microtubules and the actin cytoskeleton.
Statins reduce isoprenylation of small G proteins, in particular,
those interacting with the cytoskeleton (Kato et al. 2004;
Gazzerro et al. 2012). This has been shown for Rab5 and
Rab7 in lovastatin-treated FRTL-5 thyroid cells, which then
accumulate in the cytosol (Laezza et al. 1998). This translocation
from membrane fractions to the cytosol is explained by a de-
crease of geranylgeranylation and farnesylation, which serve as
lipid anchor for membrane insertion. Coapplication of
mevalonate, the product of the statin-inhibited HMG-CoA re-
ductase, was sufficient to prevent cytosolic accumulation of Rab
proteins (Laezza et al. 1998).
A link between reduced glycosylation and apoptosis is pro-
vided by the induction of BiP and CHOP, two sensitive markers
for ER stress (Table 2). Thus, in a scenario of dolichol deple-
tion, ER stress and reduced functional vesicular transport would
explain pro-apoptotic events and less cell surface expression of
ABCB1. However, reserve granules and intact transporters
might be present in these endosomes which may serve as a
compensatory reservoir within the first 24 h after simvastatin
application. Consequently, in add-back assays, dolichol not on-
ly overcomes deglycosylation and downregulation of ABCB1
but also reduces simvastatin-induced apoptosis (Fig. 4).
Simvastatin-induced apoptosis is also shown in our
in vivo findings. Two xenograft models confirm anti-
tumor activity of simvastatin as well as ABCB1 down-
regulation. CD-1 Nu/Nu mice inoculated with rhabdo-
myosarcoma or neuroblastoma cells received clinically
relevant simvastatin concentrations and showed a re-
markable induction of apoptosis in both tumor tissues
indicated by PARP and caspase 3 cleavages (Figs. 7
and 8). Most importantly, ABCB1 downregulation is
found in the liver and tumor tissues but did not reach
significance in neuroblastoma. Importantly, simvastatin
is capable to trigger apoptosis in neuroblastoma and
rhabdomyosarcoma. Moreover, the extent of apoptosis
is comparable to cyclophosphamide and further ampli-
fied by the combination of the two drugs, although cy-
clophosphamide is not a substrate for ABCB1 (Fig. 8).
This latter issue highlights the potential of simvastatin
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Fig. 8 Activation of caspase 3 in rhabdomyosarcoma of simvastatin-
treated animals. Rhabdomyosarcomas from animals described in Fig. 5
were used for immunohistochemistry to detect cleaved caspase 3 (a) in
controls (CTL), simvastatin (Sim)-, and/or cyclophosphamide (Cyc)-
treated groups. Nuclei were stained with Hoechst dye (green), and
cleaved caspase 3 (cl. casp 3; red). The merged pictures allow
identification of the caspase 3 translocation into the nucleus equivalent
to ongoing apoptosis (magnification ×63; white scale bars, 20 μm).
Nuclei positive for cleaved caspase 3 were counted, and normalized
data of 20 pictures from each group are depicted (b). Statistical
significance for multiple comparisons was calculated with one-way
ANOVA and post hoc Turkey test (*p<0.05; **p<0.005)
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Statins are well established and safely used compounds in the
treatment of hypercholesterolemia (Gazzerro et al. 2012).
However, anti-tumor activities caught most attention in clinical
trials and meta-analyses (Demierre et al. 2005; Gazzerro et al.
2012; Nielsen et al. 2012). Although available data are still con-
troversial and conflicting, recent studies showed that statin use
before a cancer diagnosis might be associated with lower risk of
cancer incidence and cancer-related mortality (Gazzerro et al.
2012; Nielsen et al. 2012). Notably, all-cause mortality by statin
users with cancer was reduced by 15 % (Nielsen et al. 2012).
Statins are also known to inhibit directly ABCB1, and for
the various statins, the IC50 values match congruently the
inhibition of ATP hydrolysis (Bogman et al. 2001; Wang
et al. 2001; Goard et al. 2010; Sieczkowski et al. 2010;
Werner et al. 2013). Consequently, statins enhance the intra-
cellular accumulation of ABCB1 substrates like doxorubicin,
which augments cytotoxicity in neuroblastoma and rhabdo-
myosarcoma cells and may provide the classical argument
for usage in an anti-cancer therapy (Tamplin et al. 1954;
Werner et al. 2004, 2013; Demierre et al. 2005; Goard et al.
2010; Sieczkowski et al. 2010; Tanaka et al. 2010).
In summary, simvastatin has a profound anti-tumor activity
per se, which is now further highlighted by the fact that
ABCB1 is downregulated in vitro and in vivo. Although sim-
vastatin is well tolerated, these data also implicate that drug–
drug interactions not only may take place on the level of
CYP3A4 but also have the potential to interfere with drug
extrusion via ABCB1. In fact, there is a strong overlap of
compounds, which are substrates for both proteins (Sharom
2008; International Transporter C et al. 2010). Nevertheless,
this study shows that it is feasible to downregulate ABCB1
in vitro and in vivo by simvastatin, which may act as a lead
compound in novel anti-cancer therapies.
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